Astellas Pharmaceuticals Group: Driven By Innovation
March 19, 2025 – Astellas Pharma Group (TSE: 4503) continues to demonstrate its innovative strength…
News
Aclidinium Bromide Drug: A Promising For COPD Treatment
In recent years, the pharmaceutical industry has witnessed significant advancements in the treatment of chronic…
Fulzerasib Tablets: A New Era In Targeted Cancer Therapy
In a major breakthrough for precision oncology, Fulzerasib tablets have emerged as a promising treatment…
Iclusig: A Breakthrough In The Treatment Of Drug-Resistant Leukemia
In a significant advancement in the fight against leukemia, Iclusig (ponatinib) continues to demonstrate its…
How to Use Aspaveli (Pegcetacoplan) Safely: A Complete Patient Handbook
Introduction Aspaveli (pegcetacoplan) is a C3 complement inhibitor used for the treatment of paroxysmal nocturnal…
Qalsody: A Milestone In The Treatment Of Acromegaly
April 2023 – The U.S. Food and Drug Administration (FDA) today approved Qalsody (tofersen) for…
New Hepatitis B Treatment Pradefovir Mesylate Approved In China, Bringing New Hope To Chronic Hepatitis B Patients
China’s National Drug Administration (NMPA) has officially approved the marketing application for the novel anti-hepatitis…
Jaypirca (Pitobutinib) Offers New Hope For Patients With Relapsed Refractory Hematologic Tumors
Recently, the U.S. Food and Drug Administration (FDA) announced the accelerated approval of Jaypirca (generic…
Alkindi Hydrocortisone: A Comprehensive Guide 2025
In this blog, DengYue will explore the following aspects of Alkindi Hydrocortisone: Advantages over traditional…
Talzenna Approved By FDA, Bringing New Targeted Treatment Options To Breast Cancer Patients
In October 2018, the U.S. Food and Drug Administration (FDA) approved talazoparib, a novel PARP…
Copyright@ 2016-2024 Hong Kong Deng Yue Med Al Rights